While reviewing the clinical settings of typical idiopathic intracranial hypertension (IIH), we found that there was a gap between the reports from Western countries and our domestic clinical experience [1]. The typical description of IIH is as follows: a rare condition of unknown cause, which causes increased intracranial pressure (ICP), and is characterized by symptoms related to increased ICP, especially in young obese females aged 25–45 years [2,3]. Furthermore, they suggested that a reason for the recent increase in disease incidence in Western society was probably due to the rapid increase in the obese population [4]. In our clinical experience, however, we seldom experience morbid obesity in IIH patients, the trend of which seems a little different from typical reports so far. Although we read a case report published in 2018 by Miyachi et al. [5] with interest several years ago, we failed at the time to pay attention to the body habitus of 2 young Japanese female patients described in the report. One patient was a 27-year-old female (165 cm, 48 kg), and the other was a 17-yearold young female (163 cm, 54 kg). Their body-mass indices were 17.6 kg/m² and 20.3 kg/m², respectively. The authors had already mentioned in the report that some other etiology of IIH apart from obesity must be present. This observation suggests the need for having an Asian perspective in the management of medically refractory IIH patients. Since the control of other risk factors of increased ICP is a prerequisite for the long-term durability of a stenting procedure, they emphasized the importance of persistent weight control and management of other risk factors, including obstructive sleep apnea. In reports from Western countries, the importance of weight control has been emphasized for the long-term durability of initially responsive dural sinus stenting [6]. Even bariatric surgery is considered in a refractory situation. However, measures to be taken for Asian patients, who are not overweight or may essentially be underweight, are unclear. Although Miyachi et al. [5] reported a good initial clinical response in both Asian patients, we believe they should follow up these 2 patients in the long term since dural sinus stenting is not a curative treatment for IIH. Since stenting of a collapsed sinus lumen only helps cut the vicious cycle of increased ICP, which is aggravated by secondary venous hypertension caused by extrinsic compression of the sinus, the risk of consecutive sinus lumen collapse at a non-stent segment of the sinuses remains [7]. Therefore, it is important to control the ICP stably after successful sinus stenting [8]. In this regard, identifying risk factors other than obesity in Asian patients is important. Possible risk factors, such as drug-related IIH, have already been listed [9]. Our role should be extended to the scrutinization of defining the exact cause. Furthermore, the role should also be extended in solving the enigmatic pathomechanism of this disease. We believe understanding the recently proposed concept of the glymphatic system could be undertaken as a priority for now [10].